TACE术后口服索菲拉尼治疗中晚期肝细胞癌的疗效观察及安全性评价
|
摘要
目的探讨TACE术后口服索菲拉尼治疗中晚期肝细胞癌的疗效及安全性。方法将78例中晚期肝细胞癌患者随机分为2组,各39例。对照组单纯进行TACE手术,研究组TACE术后再口服索拉菲尼。比较2组患者的临床疗效、血清相关指标、生存质量评分及不良反应情况。结果 2组患者治疗后血清ALT、AST、HIF-1α、VEGF和AFP等指标较治疗前均显著改善(P <0. 05),组间比较有统计学差异(P <0. 05)。治疗后,研究组患者的ORR及DCR明显高于对照组(P <0. 05);研究组患者生活质量改善率为66. 7%,显著优于对照组的30. 8%,差异具有统计学意义(P <0. 05)。不良反应发生率方面2组比较无统计学差异(P> 0. 05)。结论 TACE术后口服索拉菲尼治疗中晚期肝细胞癌,近期疗效明显,有助于提高患者生存质量,且无严重不良反应。
Objective To investigate the efficacy and safety of oral Sophie Rani after TACE for the treatment of advanced and advanced cell carcinoma. Methods 78 patients with intermediate and advanced hepatocellular carcinoma treated in our hospital were randomly divided into two groups,each of which was 39. The control group was operated on TACE alone,and the study group was given Sola Feeney after TACE. The clinical curative effect,serum related index,quality of life score and adverse reaction were compared between the two groups. Results Two groups of patients after treatment serum ALT,AST,HIF-1,VEGF and AFP and other indicators were significantly improved compared with before treatment( P < 0. 05),there was a significant difference between the two groups( P < 0. 05); The ORR and DCR of the patients in the study group were significantly higher than those of the control group( P < 0. 05). The improvement rate of the quality of life in the control group and study group were66. 7% and 30. 8%,and the difference was statistically significant between two groeps( P < 0. 05); Two patients with adverse reaction rate had no significant difference( P > 0. 05),the reaction after the symptomatic treatment eased. Conclusion After TACE,oral Sola Feeney is effective in the treatment of advanced and advanced cell carcinoma,which is helpful for improving the quality of life and no serious adverse reactions. It is worthy of clinical application.
Objective To investigate the efficacy and safety of oral Sophie Rani after TACE for the treatment of advanced and advanced cell carcinoma. Methods 78 patients with intermediate and advanced hepatocellular carcinoma treated in our hospital were randomly divided into two groups,each of which was 39. The control group was operated on TACE alone,and the study group was given Sola Feeney after TACE. The clinical curative effect,serum related index,quality of life score and adverse reaction were compared between the two groups. Results Two groups of patients after treatment serum ALT,AST,HIF-1,VEGF and AFP and other indicators were significantly improved compared with before treatment( P < 0. 05),there was a significant difference between the two groups( P < 0. 05); The ORR and DCR of the patients in the study group were significantly higher than those of the control group( P < 0. 05). The improvement rate of the quality of life in the control group and study group were66. 7% and 30. 8%,and the difference was statistically significant between two groeps( P < 0. 05); Two patients with adverse reaction rate had no significant difference( P > 0. 05),the reaction after the symptomatic treatment eased. Conclusion After TACE,oral Sola Feeney is effective in the treatment of advanced and advanced cell carcinoma,which is helpful for improving the quality of life and no serious adverse reactions. It is worthy of clinical application.
引文
[1]王四明.康力欣胶囊联合甘露聚糖肽治疗肝癌的临床研究[J].现代药物与临床,2016,31(6):859-862.
[2]谢而付,张丽霞,张巧娣,等.肝细胞癌患者壳多糖酶3样蛋白1与甲胎蛋白的相关性分析[J].标记免疫分析与临床,2017,24(2):159-161.
[3]冯敏,丁杰,刘颂,等.肝细胞癌患者内质网应激-凋亡信号通路的性别差异[J].江苏大学学报(医学版),2017,27(5):432-436.
[4]中国抗癌协会肝癌专业委员会.原发性肝癌临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324.
[5]Lencioni R,Llovet JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Seminars in Liver Disease,2010,30(1):52.
[6]刘岗,钟武装,赵玮,等.索拉非尼联合TACE术治疗中晚期肝细胞癌的临床疗效分析[J].实用癌症杂志,2016,31(12):1970-1973.
[7]陈建武.肝细胞癌合并胆管癌的临床分型以及手术方式选择对疾病预后的影响[J].实用癌症杂志,2017,32(6):950-952.
[8]顾雅雯,刘琳.索拉非尼联合其他化疗药物治疗晚期肝细胞癌的临床研究进展[J].东南大学学报(医学版),2016,35(05):793-796.
[9]Dickinson B,Surawicz CM.Infectious diarrhea:an overview[J].Current Gastroenterology Reports,2014,16(8):399.
[10]樊斌,张家耀,张勇,等.原发性肝细胞癌患者血清TATIP2/TIP30、RBBP4水平与临床病理的关系[J].检验医学与临床,2016,13(23):3414-3416.
[11]刘薇,刘朝敏,王少龙.肝癌患者TACE术后血清VEGF、HIF-1α、CRP水平与肝癌复发的相关性分析[J].标记免疫分析与临床,2015,22(4):300-303.
[12]姜海英,谢晓东.索拉非尼联合TACE术治疗中晚期肝细胞癌30例临床观察[J].海南医学,2010,21(23):6-9.
[2]谢而付,张丽霞,张巧娣,等.肝细胞癌患者壳多糖酶3样蛋白1与甲胎蛋白的相关性分析[J].标记免疫分析与临床,2017,24(2):159-161.
[3]冯敏,丁杰,刘颂,等.肝细胞癌患者内质网应激-凋亡信号通路的性别差异[J].江苏大学学报(医学版),2017,27(5):432-436.
[4]中国抗癌协会肝癌专业委员会.原发性肝癌临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324.
[5]Lencioni R,Llovet JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Seminars in Liver Disease,2010,30(1):52.
[6]刘岗,钟武装,赵玮,等.索拉非尼联合TACE术治疗中晚期肝细胞癌的临床疗效分析[J].实用癌症杂志,2016,31(12):1970-1973.
[7]陈建武.肝细胞癌合并胆管癌的临床分型以及手术方式选择对疾病预后的影响[J].实用癌症杂志,2017,32(6):950-952.
[8]顾雅雯,刘琳.索拉非尼联合其他化疗药物治疗晚期肝细胞癌的临床研究进展[J].东南大学学报(医学版),2016,35(05):793-796.
[9]Dickinson B,Surawicz CM.Infectious diarrhea:an overview[J].Current Gastroenterology Reports,2014,16(8):399.
[10]樊斌,张家耀,张勇,等.原发性肝细胞癌患者血清TATIP2/TIP30、RBBP4水平与临床病理的关系[J].检验医学与临床,2016,13(23):3414-3416.
[11]刘薇,刘朝敏,王少龙.肝癌患者TACE术后血清VEGF、HIF-1α、CRP水平与肝癌复发的相关性分析[J].标记免疫分析与临床,2015,22(4):300-303.
[12]姜海英,谢晓东.索拉非尼联合TACE术治疗中晚期肝细胞癌30例临床观察[J].海南医学,2010,21(23):6-9.